Patents Examined by Rebecca L. Anderson
  • Patent number: 10406126
    Abstract: The present invention provides a compound represented by formula (1): or pharmaceutically acceptable salt thereof, wherein X and Y are the same or different from each other and represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group, wherein the C1-6 alkoxy group may be substituted with a C1-6 alkoxy group, and Z and W are the same or different from each other and represent a hydrogen atom, a halogen atom, or a C1-6 alkyl group.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: September 10, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Keigo Tanaka, Tasuku Ishida, Masayuki Miyano, Raku Shinkyo
  • Patent number: 10392376
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: August 27, 2019
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Suyambu Kesava Vijayan Ramaswamy, Michael Garrett Johnson, Sarah Lively, David Lapointe
  • Patent number: 10383874
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: August 20, 2019
    Assignee: Merk Patent GMBH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Patent number: 10385061
    Abstract: A compound and use thereof are provided. The compound of the invention has formula I shown below. Each variable in formula I, is defined in the specification. The invention also provides a method for treating renal and cardiac dysfunction. The method includes administering to a subject in need thereof an effective amount of the compound of the invention and a pharmaceutical acceptable salt and carrier.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 20, 2019
    Assignee: Phytohealth Corporation
    Inventors: Kuo-Hsiung Lee, Rong-Tsun Wu, Xiao-Ming Yang, Yu Zhao, Lin-Yea Horng, Hui-Ching Sung, Pei-Lun Hsu, Chien-Hsin Cheng, Yi-Li Lee
  • Patent number: 10385249
    Abstract: A hydrofluoroether compound represented by the following general formula:
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: August 20, 2019
    Assignee: 3M Innovative Properties Company
    Inventors: Michael J. Bulinski, Michael G. Costello, William M. Lamanna, Georgiy Teverovskiy, Kiah A. Smith
  • Patent number: 10383879
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 20, 2019
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • Patent number: 10377708
    Abstract: The various aspects present inventions provide various crystalline forms of (S)-(?)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: August 13, 2019
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John R. Snoonian, Harold Scott Wilkinson
  • Patent number: 10377755
    Abstract: The disclosure includes compounds of Formula (I) wherein W, R1, R2, R3, R4, R5, R6, m, n, L, and Z1, are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: August 13, 2019
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • Patent number: 10358435
    Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: July 23, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Dong-Ming Shen, Christopher J. Sinz, Alejandro Crespo, Johnathan E. Wilson, Troy McCracken, Shimin Xu, Haitang Li
  • Patent number: 10349657
    Abstract: The present invention relates to compounds of the general formula (I) in which Q, V, T, W, X, Y and A have the meanings given in the description—and to their use for controlling animal pests.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: July 16, 2019
    Inventors: Markus Heil, Reiner Fischer, Johannes-Rudolf Jansen, Matthieu Willot, Susanne Kübbeler, David Wilcke, Kerstin Ilg, Peter Lösel, Sascha Eilmus, Wolfram Andersch, Daniela Portz, Ulrich Görgens
  • Patent number: 10344028
    Abstract: Provided are a novel organic semiconductor compound, a production method thereof, and an organic electronic device using the same, wherein the organic semiconductor compound includes a thiazolidine functional group introduced into a heteroaromatic ring to thereby remarkably improve photovoltaic characteristics of an organic electronic device including the same.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 9, 2019
    Assignees: Korea Research Institute of Chemical Technology, Kyonggi University Industry & Academia Cooperation Foundation
    Inventors: Jong Cheol Lee, Sang Kyu Lee, Won Suk Shin, ChangEun Song, Sang Jin Moon, Hang Ken Lee, Eunhee Lim
  • Patent number: 10335415
    Abstract: Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: July 2, 2019
    Assignee: MEI PHARMA, INC.
    Inventors: S. David Brown, David J. Matthews
  • Patent number: 10336771
    Abstract: The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1?, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: July 2, 2019
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Paul E. Erdman, Leah Fung, Frank Mercurio, Robert Sullivan, Eduardo Torres
  • Patent number: 10336770
    Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: July 2, 2019
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Chenggeng Qian
  • Patent number: 10335393
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: July 2, 2019
    Assignee: Biogen MA Inc.
    Inventors: Vincent Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
  • Patent number: 10329310
    Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of arginase 1 and arginase 2 activity. The inventions also provides pharmaceutical compositions and methods for using the inventive compounds for treating or preventing a disease or condition associated with arginase activity.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: June 25, 2019
    Assignee: Onco Arendi Therapeutics S.A.
    Inventors: Roman Blaszczyk, Joanna Brzezinska, Adam A. Golebiowski, Jacek Olczak
  • Patent number: 10329249
    Abstract: The sulindac derivatives are compounds of the formula: wherein R is one of twenty-five substituted or unsubstituted phenyl substituents; and pharmaceutically acceptable salts thereof. The sulindac derivatives are synthesized by refluxing sulindac hydrazide with appropriately substituted benzaldehydes in the presence of ethanol and catalytic amounts of glacial acetic acid. The sulindac derivatives may be used as active ingredients in pharmaceutical compositions for the treatment of inflammation or inflammatory diseases. The sulindac derivatives may also be used as analgesic and/or gastric sparing agents.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: June 25, 2019
    Assignee: King Saud University
    Inventors: Mashooq Ahmad Bhat, Mohamed A. Al-Omar, Nawaf Abdulaziz Alsaif, Syed Hidayathulla
  • Patent number: 10323001
    Abstract: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present invention also provides a novel polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: June 18, 2019
    Assignee: Athenex, Inc.
    Inventors: David G. Hangauer, Jr., Debasis Patra, Jeremy A. Cody, Grant J. Palmer, Paul K. Isbester, Jonathon Salsbury
  • Patent number: 10314845
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 11, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Rosanna Tedesco, Junya Qu, Robert Sanchez, Ralph A. Rivero
  • Patent number: 10316021
    Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (?-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: June 11, 2019
    Assignee: Pfizer Inc.
    Inventors: Natasha Mariam Kablaoui, Michael Eric Green, Justin Ian Montgomery, Michael Aaron Brodney, Patrick Robert Verhoest, Gregory Wayne Kauffman, Danica Antonia Rankic, Scot Richard Mente, Bruce Nelsen Rogers, Kapildev Kashmirilal Arora, Matthew Francis Dunn